A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Cancer: Lung
Study Phase: phase 1
Status: recruiting
Sponsor: Ankyra Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT07027514
Disease Focus: Non Small Cell Lung Cancer
Principal Investigator: Jun Zhang MD PhD
Clinical Research Coordinator: Vishnu JaiShree Mohandas MBBS MPH

Study Overview

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

clinicaltrials.gov NCT:NCT07027514

Interested in Participating in this Trial?

If you are interested in participating in this study, call the OSF Hope line at (844) 673- 4467 or email: sfmc.clinicaltrials@osfhealthcare.org